期刊
SENSORS AND ACTUATORS B-CHEMICAL
卷 129, 期 1, 页码 424-430出版社
ELSEVIER SCIENCE SA
DOI: 10.1016/j.snb.2007.08.047
关键词
biomimetic sensor; phenolic compound; pharmaceutical formulation
The dinuclear iron complex, [(FeFeII)-Fe-III(BPBPMP)(OAc)(2)]ClO4, containing the unsymmetrical ligand, 2-bis[{(2-pyridylmethyl)-aminomethyl}-6-{(2-hydroxybenzyl)(2-pyridylmethyl)}-aminomethyl]-4-methylphenol (H2BPBPMP), has been described as being the first synthetic analogue for the redox properties of uteroferrin. This iron complex was employed in the construction of a new biomimetic sensor for the determination of phenolic compounds by square-wave voltammetry. The responses under optimized conditions were obtained for a 75:15:10% (w/w/w) composition of the graphite powder:Nujol:iron complex, 0.1 mol L-1 phosphate buffer solution (pH 7.0) and 4.5 x 10(-5) mol L-1 hydrogen peroxide. From the several phenolic compounds available (carbidopa, catechol, dopamine, hydroquinone, L-dopa and methyldopa), dopamine was selected, used for optimization of the biomimetic sensor and applied in determinations in pharmaceutical formulations. The analytical curve was linear for dopamine concentrations from 5.0 x 10(-5) to 6.5 x 10(-3) mol L-1 (r = 0.9993). The recovery of dopamine from pharmaceutical sample ranged from 95.8 to 104.2% and the relative standard deviation was 2.6% for a solution containing 3.0 x 10(-3) mol L-1 dopamine (n = 12). The lifetime of this biomimetic sensor was 6 months (at least 800 determinations). The results obtained for dopamine in pharmaceutical samples using the proposed biomimetic sensor and those obtained by the official method are in agreement at the 95% confidence level. (C) 2007 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据